|Active Ingredients||% w/w|
|Zinc Oxide||Ph Eur||5|
Occasional hypersensitivity or irritant reactions.
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard or search MHRA Yellow card on the Apple App or google Play Store.
|Date of First Authorisation:||9 November 1984|
|Last Renewal:||22 December 1994|